CEAT project for improving ovarian cancer diagnosis, treatment shows promise

Porvair Sciences reports, due to promising results, it has agreed with its collaborative partners to make additional investment in the CEAT project which aims to dramatically improve the diagnosis and treatment of ovarian cancer.

CEAT project for improving ovarian cancer diagnosis, treatment shows promise

In the initial stage of the CEAT (Cluster for Epigenomic and Antibody Drug Conjugate Therapeutics) project - Porvair Sciences supplied its proprietary Chromatrap® bead-free Chromatin Immunoprecipitation (ChIP) technology to help University of Swansea researchers develop new epigenomic profiling approaches to enable advances in drug development and patient profiling.

So far the project has had success in developing bespoke chemo-resistant OC cell lines, optimized the Chromatrap® kits for 3D spheroid analysis along with biochemical analysis on AFM (Atomoic Force Microscopy). The expansion to the project will allow current microrheology assessment of disease phenotype spheroid culture models and high resolution binding kinetics to support selective targeting and drug mechanism of action.

Our further involvement in this exciting project will be now to launch the optimized ChIP kits for 3D spheroid analysis. These novel ChIP kits will enable assessment of disease phenotypes on spheroid culture models thereby providing a valuable insight to understanding drug target mechanisms and selectivity".

Amy Johnson, Business and Technical Development Manager, Porvair Sciences

The CEAT  project is now valued at over £5m, principially led by the Swansea University Medical School, and in collaboration with 6 industrial partners, (Porvair Sciences Ltd, Bruker UK, Cytiva UK, Axis Bioservices and GlaxoSmithKline (GSK). The project is focused on developing  advanced drug technologies for the treatment of ovarian cancer. Key aims of the CEAT project are creation of novel epigenetic drugs using cross cutting technology approaches; development of techniques to identify patients that will benefit from targeted epigenetic and non-epigenetic drug treatments and generation of novel antibody drug conjugates (ADC's) effective against ovarian cancer.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Porvair Sciences Limited. (2020, November 16). CEAT project for improving ovarian cancer diagnosis, treatment shows promise. News-Medical. Retrieved on June 18, 2024 from https://www.news-medical.net/news/20201116/CEAT-project-for-improving-ovarian-cancer-diagnosis-treatment-shows-promise.aspx.

  • MLA

    Porvair Sciences Limited. "CEAT project for improving ovarian cancer diagnosis, treatment shows promise". News-Medical. 18 June 2024. <https://www.news-medical.net/news/20201116/CEAT-project-for-improving-ovarian-cancer-diagnosis-treatment-shows-promise.aspx>.

  • Chicago

    Porvair Sciences Limited. "CEAT project for improving ovarian cancer diagnosis, treatment shows promise". News-Medical. https://www.news-medical.net/news/20201116/CEAT-project-for-improving-ovarian-cancer-diagnosis-treatment-shows-promise.aspx. (accessed June 18, 2024).

  • Harvard

    Porvair Sciences Limited. 2020. CEAT project for improving ovarian cancer diagnosis, treatment shows promise. News-Medical, viewed 18 June 2024, https://www.news-medical.net/news/20201116/CEAT-project-for-improving-ovarian-cancer-diagnosis-treatment-shows-promise.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
High performance microplates for enhanced cell growth and survival